Prostate cancer (PC) is the second most frequently diagnosed cancer and the second leading cause of cancer deaths in man. The estimate of new diagnoses and deaths from PC in 2012, in the United States, amounted to 241,740 and 28,170, respectively (American Cancer Society, 2012). In Italy, it has been estimated that every year 23,518 new PCs are diagnosed; deaths due to PC are 7,105 (AIRT, 1998–2002). PC incidence and mortality displays geographic variation, with high rates of incidence and mortality in the US and Western Europe, and low rates in Asia (Makridakis et al., 1997; Figure 1).

Data show that mortality from PC is relatively lower compared to the total number of yearly diagnosed cases. Therefore most patients die with this disease rather than from it (Nelson et al., 2008). The treatment of localized PCs includes surgery or radiation therapy. In cases of relapse after a definitive treatment or in patients with locally advanced or metastatic disease, the standard treatment includes the androgen-deprivation therapy (ADT). By reducing the levels of testosterone and dihydrotestosterone under the castration threshold, the ADT acts on the androgen receptor (AR), even if indirectly. The effects of the ADT are usually temporary and nearly all patients, initially sensitive to the androgen ablation therapy, have a disease progression after an 18–24 months medium term. This is probably due to the selection of the cancer cell clones and to their acquisition of critical somatic genome and epigenomic changes. This review aims to provide an overview about the genetic and epigenetic alterations having a crucial role in the carcinogenesis and in the disease progression toward the castration resistant PC. We focused on the role of the AR, on its signaling cascade and on the clinical implications that the knowledge of these aspects would have on hormonal therapy, on its failure and its toxicity.

Keywords: prostate cancer

INTRODUCTION

Prostate cancer (PC) is the second most frequently diagnosed cancer and the second leading cause (the first one is lung cancer) of cancer deaths in man. The estimate of new diagnoses and deaths from PC in 2012, in the United States, amounted to 241,740 and 28,170, respectively (American Cancer Society, 2012). In Italy, it has been estimated that every year 23,518 new PCs are diagnosed; deaths due to PC are 7,105 (AIRT, 1998–2002). PC incidence and mortality displays geographic variation, with high rates of incidence and mortality in the US and Western Europe, and low rates in Asia (Makridakis et al., 1997; Figure 1).

Data show that mortality from PC is relatively lower compared to the total number of yearly diagnosed cases. Therefore most patients die with this disease rather than from it (Nelson et al., 2008). The treatment of localized PCs includes surgery or radiation therapy. In cases of relapse after a definitive treatment or in patients with locally advanced (T3b to T4) or metastatic disease (N1 or M1), the standard treatment includes the androgen-deprivation therapy (ADT; Huggins and Hodges, 2002). The ADT aims to reduce the circulating levels of testosterone around or below levels present in castration (<50 ng/ml). The reason behind the use of hormone therapy in the PC treatment is that the tumor becomes able to maintain an incentive to grow in spite of very low serum levels of testosterone. This review aims to provide an overview about the genetic and epigenetic alterations having a crucial role in the carcinogenesis and in the disease progression toward the castration resistant PC. We focused on the role of the AR, on its signaling cascade and on the clinical implications that the knowledge of these aspects would have on hormonal therapy, on its failure and its toxicity.

GENOMIC ALTERATIONS

Genomic alterations with a potential involvement in PC include somatic mutations, gene deletions or amplifications, chromosomal rearrangements. In the natural history of PC these alterations
are probably accumulated over a period of several decades. The first studies on the molecular changes, with a potential crucial role in the development of PC, have identified chromosomal abnormalities frequently reported in PC patients, such as the gain of genetic material in 7p, 7q, 8q, and Xq and losses in 8p (Helcomb et al., 2009), 10q, 13q, and 16q. Some studies have shown that a chromosomal translocation involving TMPRSS2 (PSA-regulated gene transmembrane protease, serine 2), an androgen-responsive gene and a member of the ETS family of transcription factors (ERG, ETV1, ETV4, or ETV5) is present in over 60% of localized
The incidence of the TMPRSS2–ERG fusion is almost 60% in PC. Both genes are localized on chromosome 21q22 and the fusion takes place by an interstitial deletion. Translocations involving other ETS family members occur rarely. Seventeen different TMPRSS2–ERG fusions, involving different regions of the TMPRSS2 and the ERG, have been identified. Eight of these fusions do not encode functioning ERG proteins for the introduction of a premature stop codon. Nine give rise to functional fusion products: two encode the normal ERG protein, six truncated ERG proteins, and one is a new protein resulting from the TMPRSS2 and the ERG fusion. The
biological consequence of these different products is unknown. The TMPRSS–ERG translocation is considered an early event in the development of PC; it is not present in prostate benign lesions or hyperplasia. However, this is probably not the initial event as it is observed only in 20% of the PIN and it does not seem to have a direct role in the progression to adenocarcinoma. These data suggest that additional genetic mutations must occur. Alterations were also identified in signal pathways of growth factors (NRX3.1, PTEN, c-MYC, and p27) and in the AR axis as determinants of the cancer cell phenotype. The LOH of 9p21.2 is found in 60% of the PIN and 85% of PC. The transcription factor NRX3.1 AR-regulated, whose normal function is to facilitate the terminal differentiation of prostatic epithelial cells, maps in this location. It has been suggested that the NRX3.1 is a gatekeeper tumor suppressor gene, similar to the APC, in the colon cancer, to the VHL in renal clear cell carcinoma and to the RB in retinoblastoma. In contrast to peculiar tumor suppressor genes, however, allele of the NRX3.1 has not changed and the loss of heterozygosity determines a reduction of protein levels. The amplification of chromosome 8q24 associated to the over-expression of the transcription factor MYC is more frequently observed in PIN and in localized or metastatic PC. The decrease of p27, a cell cycle inhibitor, is correlated with an increase in histological grade of PC and with the risk of relapse. The LOH 12q12-13 containing p27 is present in 20% of localized disease cases and in approximately 50% of metastatic disease (Mackinnon et al., 2009). Also, single-nucleotide polymorphisms (SNPs) in key genes have been hypothesized to be associated with PC risk, outcome, and responsiveness to therapies. With respect to this topic, a meta-analysis based on 38 studies involving 34,782 cases of PC and 38,626 controls, suggested that the SNP of the CYP17 gene, in a meta-analysis based on 38 studies involving 34,782 cases of PC and 38,626 controls, suggested that the SNP of the CYP17 gene, a well-known epigenetic mechanism is DNA methylation, changes to chromatin and alterations of microRNAs expression. Considerable evidences exist that a global DNA hypomethylation occurs late in PC contributing to the disease progression by promoting genomic instability (Chin et al., 2011). The inactivation of specific genes, caused by silencing their transcription through epigenetic alterations, is largely known as one of the mechanisms which can contribute to carcinogenesis. Among these epigenetic alterations in PC, the aberrant methylation of DNA in the promoter region of some genes (like GSTP – pi-class glutathione S-transferase) is a significant event (Lee et al., 1994). The somatic inactivation of the GSTP, which is a gene involved in detoxification, is the result of an aberrant methylation (hypermethylation) of CpG islands located in the gene promoter. As a result of this alteration the cells are more prone to accumulate additional mutations. This event seems to be involved in an early stage of the prostatic carcinogenesis: it is present in 70% of high-grade PIN and in more than 90% of adenocarcinomas (Nakayama et al., 2003; Kang et al., 2004). Li et al. (2001) observed that the degree of hypermethylation of E-cadherin gene (a gene in maintenance of normal cell architecture involved) in PC tissue was correlated with the pathological stage. They found an hypermethylation of E-cadherin gene promoter into the 30% of low-grade and the 70% of high-grade tumor tissues, respectively. Furthermore, hypermethylation of the p16 gene promoter results in a proliferative advantage of the cell clone so modified, with obvious implications, both in carcinogenesis and in the disease progression (Larrard et al., 1997; Gu et al., 1998). In about 66% of PC the expression of the PTEN, an inhibitor of the PI3K/Akt pathway, is reduced or absent, with consequent activation of the PTEN/PI3K/Akt/mTOR pathway. PTEN loss of function can result from deletion, mutation or epigenetic gene silencing. The PTEN transcript is silenced in ADVANCE and androgen-repressed transcriptional silencing is often consequence of the CpG islands methylation located in its promoter region and would have a role in disease progression (Caetano et al., 1999; Suzuki et al., 1998). In some PC, the DNA hypermethylation could be also involved in the regulation of the AR expression. Suzuki et al. (2003) data showed that in 50% of hormone-refractory PC, the expression of the AR may be lost as a result of the AR promoter gene hypermethylation. Similarly the hypermethylation and consequent upregulation of genes like heparanase, urokinase may contribute to tumor cell invasion and metastasis (Hufett et al., 1999; Pakhomov et al., 2003). More examples of genes frequently silenced in PC are the APC, the MGMT, and the MDR1 (Kang et al., 2004).

CASTRATION RESISTANT PROSTATE CANCER AND AR

The issue of androgen independence has been recently reviewed in light of the new knowledge achieved, so much so that today the term of resistance to castration is preferred. It is known that in the process of PC progression, the AR signaling axis maintains a decisive role: PC cells, once become resistant to castration, can evade the ADT cell growth inhibition and continue to express androgens-regulated genes even with castration serum levels of androgens. This should be partly explained by genetic alterations on the AR. As demonstrated in literature, AR alterations are observed in more than 50% of metastatic PC cases and tend to be rare in limited disease (Marcelli et al., 2000). It is yet unclear when the tumor acquires genetic alterations leading to castration resistance. While some studies suggest that tumor acquires these genetic alterations regardless of the ADT, other data highlight that the ADT would exert selective pressure on tumor cells. In this way the ADT would select cell clones able to grow independently from androgens, thanks to AR mutations (Taplin et al., 1993). The AR is a nuclear transcription factor whose gene belongs to the steroid–thyroid–retinoid nuclear receptor super-family. The AR gene is located on the X chromosome and contains eight exons. It encodes a protein of 919 amino acids. The AR is composed of four different domains: the N-terminal domain (NTD), the deoxyribonucleic acid-binding domain (DBD), the hinge region, and the ligand-binding domain (LBD; Lonergan and Tindall, 2011). AR aberrations correlated to the long-term failure of the ADT include the AR amplification/over-expression, the alternative source of androgens, the mutated AR or promiscuous AR, the
over-expression of AR co-regulators, the AR activation by CK or growth factors. Nevertheless, the AR continues to be expressed even in disease advanced stages, regardless sensitivity to hormonal therapy (van der Kast et al., 1991; Hobisch et al., 1995).

**AR AMPLIFICATION/OVER-EXPRESSION**

The amplification of the AR gene has been associated with endocrine therapy failure. In a Finnish study on 54 patients, this specific alteration was found in about 30% of locally recurrent or metastatic hormone-refractory tumors, while absent in the untreated ones. Käristö et al. (1997) concluded that AR amplifications occurs exclusively during the disease progression after the ADT and it is more frequent in tumors with an initial good response to the hormone therapy. Indeed, tumor cells in this case would be more critically dependent on androgen than in patients primarily resistant to ADT. Also, recurrent tumors with the AR gene amplification treated with a first-line hormonal monotherapy, could benefit from a second-line combined androgen blockade, more than patients without this AR alteration, although this does not mean a gain in survival (Palmberg et al., 2000). Gregory et al. (2004) also confirms that the basis of castration resistance may consist in an hypersensitivity of the AR, resulting from its over-expression, increased stability and intranucleolar localization.

**ALTERNATIVE SOURCE OF ANDROGENS**

In spite of extremely low levels of circulating androgens, the CRPC progression remains dependent on the androgen–driven activity and PC cells keep the AR pathway active in different ways. An hypothesis standing to explain this observation is that alternative sources of androgenic steroids exist. Pioneer works, confirmed by recent researches in this area, indicated that intraprostatic amount of testosterone and DHT remains moderately high despite their castration serum levels (Liu et al., 1985; Labrie, 2004; Tunin et al., 2005). Locke et al. (2008) hypothesized that androgens de novo synthesized within prostatic tumor tissue may drive the CRPC progression in the absence of testicular androgens. Also they argue that some enzymes necessary for androgens synthesis (SRD5A1, RDH5, ARK1C1,2,3) are up-regulated in PC cells during the CRPC progression. Montgomery et al. (2008) remarked this theory showing that all the enzymes involved in the biosynthesis of testosterone and DHT were expressed in the majority of metastatic CRPC examined in his study. This would explain how the decrease of DHT in prostate tissue after the ADT may not be proportional to decreased levels of circulating testosterone (60 vs. 95% respectively; Labrie et al., 1986). What also appears to be assumed is that the adrenal steroids peripheral conversion may be sufficient to the androgen independent PC cell lines (PC-3) compared to the androgen-dependent ones (DU-145, LNCaP). The AR-associated protein ARA70 expression was sized that its amplification or mutation in primary and metastatic PC enhances the androgen-dependent AR transcriptional activity. The steroid receptor co-activator (SRC) family includes the SRC-1, the SRC-2, and the SRC-3. Literature shows that the SRC-1 is over-expressed in ADT-refractory PCa. Gregory et al. (2004) found that the SRC-2 is also over-expressed in recurrent PCs. This change may contribute to PC relapse after endocrine therapy. There is no clear evidence about the possible roles of the SRC-3 in prostate tumor development and progression. The steroid receptor RNA activator (SRA) is another co-activator for steroid receptors which functions as a RNA transcript in a ribonucleoprotein complex containing the SRC-1. Kawashima et al. (2002) showed that the SRA expression is higher in androgen-independent PC cell lines (PC-3) compared to the androgen-dependent ones (DU-145, LNCaP). The AR-associated protein ARA70 can interact with the AR and modulate its transcriptional activity in response to the androgens stimulation. SRA expression also seems to be regulated by both ER and AR in PC cells (Tak et al., 2001).

**THE AR ACTIVATION BY CK AND GROWTH FACTORS**

The possibility of a cross-talk between the AR pathway and intra-cellular signaling cascades activated by IGF-1, KGF, and EGF.
leading to transcription of androgen controlled genes, in the absence of the ligand exists (Calig et al., 1994). The ErbB or HER receptor network is frequently altered in solid tumors. The HER kinase family includes the epidermal growth factor receptor (EGFR or ErbB1), the human epidermal growth factor receptor 2 (HER2), the ErbB3 (HER3), and the ErbB4 (HER4). The HER2 is the only one in a fixed open conformation, other members need to bind to the ligand to form active dimer instead (Solfi and Rosen, 2007). In breast cancers, the ErbB2 over-expression correlates with estrogen independence. In the ErbB2 over-expressed breast cancers therapy the anti-HER2 monoclonal antibody, trastuzumab (Herceptin) can be used. Similar to the breast cancer case, or even in PC (Sgncorreti et al., 2000), it may exist a connection between the over-expression of the HER2/neu (also known as ErbB2) and the progression to castrate resistant disease. The activation of the HER2 signaling cascade may lead to constitutive activation of the AR (Craft et al., 1999; Yeh et al., 1999). Studies suggest that the ErbB receptor activation may be important in the growth and in the survival of both androgen-dependent and androgen-independent PC (Agus et al., 2002). In particular, the ErbB2–ErbB3 signaling has been implicated in enhancing the AR signaling through modulation of its transcriptional activity and its degradation in the presence of low androgen levels (Mellingerhoff et al., 2004). Wen et al. (2000) showed in LNCaP cells that the HER2/neu activates Akt (protein kinase B) and in this way promotes the PC cells survival and growth in absence of androgens. These conditions may open new ways to PC therapy. However, when trastuzumab (Lara et al., 2004; Ziada et al., 2004) and pertuzumab (a second generation of anti-HER2 monoclonal antibody; De Bono et al., 2007), as well as the EGFR tyrosine kinase inhibitors (TKIs) gefitinib (Canil et al., 2005) and erlotinib (Gravis et al., 2006) have been tested in PC, it was observed a non-significant single-agent activity. These results suggest that these targets may be of secondary importance or of primary importance only in few cases of PC. According to the disappointing results obtained by the single use of these molecules, some researchers attempted to test them in combination. These therapeutic strategies aim to get the return of prostatic cancer cells to the androgen sensibility. Distinct phase II studies, show that three EGFR inhibitors have been combined with docetaxel. In single-arm studies of the gefitinib or erlotinib, PSA response rates are modest, although the erlotinib showed favorable survival (24.6 months) with increased toxicity (Gross et al., 2007; Salberg et al., 2007). Recent evidences also suggest that the HER-2 expression confers an increased risk of CNS metastases in the metastatic CRPC (Germone et al., 2011). Other factors not directly related to the AR are certainly involved in the carcinogenesis and progression of PC. Data from some studies point to the potential role of proteins involved in the regulation of vascular permeability and endothelial proliferation. In 2006, a study shown that the endothelium-derived vascular endothelial growth factor/prokinetin 1 and 2 (EG-VEGF/PK1 and 2) and their receptors were expressed after the transition from benign to malignant prostatic glandular epithelium and that their levels increased with increasing histological grade (Pasquali et al., 2006).
metastatic CRPC in both first-line (in combination with docetaxel) and second-line treatment (in men progressing during or after treatment with docetaxel). Phase III clinical studies are ongoing on molecules with different targets: the androgen signaling pathway (MDV3100, Scher et al., 2010; TAK-700, Driscoll et al., 2010) has demonstrated significant activity in phase I and II studies (Milowsky et al., 2004; Bander et al., 2005; Tagawa et al., 2008, 2010). However, resistance to the first-line chemotherapy occurs, inevitably, in patients who initially responded. Studies were designed in order to overcome this obstacle in different ways. Some researchers attempted associating docetaxel to a molecule able to interfere with one or more mechanisms of chemotherapy resistance. The aim is to improve the efficiency of a well-known cytotoxic agent to carry out its task. On the basis of encouraging results of a phase II trial, Chi et al. (2009) employed this strategy in a phase III study using the antisense oligonucleotide: the custisine (OGX-011). Evidence in literature also indicate that tumor microenvironment may be critically implicate in PC therapy resistance. In particular angiogenic growth factors like vascular endothelial growth factor (VEGF) may have a crucial role in mechanisms guiding bone metastatization and disease progression. So recently attention has been paid to the use of docetaxel in conjunction with stroma-targeting molecules.

CONCLUSION Nowdays treatment options available for the CRPC are many and new questions emerge. First, how these new drugs have to be administered in clinical practice. In the era of the personalized cancer therapies, the deep knowledge of underlying mechanisms of the castration resistance of PC has become a topic of primary importance. Research in this field aims to obtain the tools in order to choose the most effective and less toxic therapy for each patient. This is more evident if we think about the impact of the hormone therapy on patients with PC quality life. In this way risks and benefits, ratio of a single therapy, have a greater significance. New biomarkers able to predict which patients may really benefit from a specific therapy without being exposed to an unnecessary toxicity, are required. For the future it should be possible to understand the genetic background of our patients with regard to some critical enzymes which could influence both response and resistance to drugs, before starting a specific therapy. This chance could make it really feasible to personalize the therapy in individual patients.

REFERENCES Agos, D. B., Altuk, B. R., Fox, W. D., Lewis, G. D., Higgins, B., Plascenc, P. I., et al. (2002). Targeting lipid-activated ERBB2 signaling with breast and prostate tumor growth. Cancer Cell 2, 127–137.

Ascheter et al. Genomic and epigenomic alterations in prostate cancer

Araujo, J., Armstrong, A. J., Braud, E. (2009) employed this strategy in a phase III study. On the basis of encouraging results of a phase II study, Milowsky et al., 2004; Bander et al., 2005; Tagawa et al., 2008, 2010). However, resistance to the first-line chemotherapy occurs, inevitably, in patients who initially responded. Studies were designed in order to overcome this obstacle in different ways. Some researchers attempted associating docetaxel to a molecule able to interfere with one or more mechanisms of chemotherapy resistance. The aim is to improve the efficiency of a well-known cytotoxic agent to carry out its task. On the basis of encouraging results of a phase II trial, Chi et al. (2009) employed this strategy in a phase III study using the antisense oligonucleotide: the custisine (OGX-011). Evidence in literature also indicate that tumor microenvironment may be critically implicate in PC therapy resistance. In particular angiogenic growth factors like vascular endothelial growth factor (VEGF) may have a crucial role in mechanisms guiding bone metastatization and disease progression. So recently attention has been paid to the use of docetaxel in conjunction with stroma-targeting molecules.

CONCLUSION Nowdays treatment options available for the CRPC are many and new questions emerge. First, how these new drugs have to be administered in clinical practice. In the era of the personalized cancer therapies, the deep knowledge of underlying mechanisms of the castration resistance of PC has become a topic of primary importance. Research in this field aims to obtain the tools in order to choose the most effective and less toxic therapy for each patient. This is more evident if we think about the impact of the hormone therapy on patients with PC quality life. In this way risks and benefits, ratio of a single therapy, have a greater significance. New biomarkers able to predict which patients may really benefit from a specific therapy without being exposed to an unnecessary toxicity, are required. For the future it should be possible to understand the genetic background of our patients with regard to some critical enzymes which could influence both response and resistance to drugs, before starting a specific therapy. This chance could make it really feasible to personalize the therapy in individual patients.

REFERENCES Agos, D. B., Altuk, B. R., Fox, W. D., Lewis, G. D., Higgins, B., Plascenc, P. I., et al. (2002). Targeting lipid-activated ERBB2 signaling with breast and prostate tumor growth. Cancer Cell 2, 127–137.

Ascheter et al. Genomic and epigenomic alterations in prostate cancer

Araujo, J., Armstrong, A. J., Braud, E. (2009) employed this strategy in a phase III study. On the basis of encouraging results of a phase II study, Milowsky et al., 2004; Bander et al., 2005; Tagawa et al., 2008, 2010). However, resistance to the first-line chemotherapy occurs, inevitably, in patients who initially responded. Studies were designed in order to overcome this obstacle in different ways. Some researchers attempted associating docetaxel to a molecule able to interfere with one or more mechanisms of chemotherapy resistance. The aim is to improve the efficiency of a well-known cytotoxic agent to carry out its task. On the basis of encouraging results of a phase II trial, Chi et al. (2009) employed this strategy in a phase III study using the antisense oligonucleotide: the custisine (OGX-011). Evidence in literature also indicate that tumor microenvironment may be critically implicate in PC therapy resistance. In particular angiogenic growth factors like vascular endothelial growth factor (VEGF) may have a crucial role in mechanisms guiding bone metastatization and disease progression. So recently attention has been paid to the use of docetaxel in conjunction with stroma-targeting molecules.

CONCLUSION Nowdays treatment options available for the CRPC are many and new questions emerge. First, how these new drugs have to be administered in clinical practice. In the era of the personalized cancer therapies, the deep knowledge of underlying mechanisms of the castration resistance of PC has become a topic of primary importance. Research in this field aims to obtain the tools in order to choose the most effective and less toxic therapy for each patient. This is more evident if we think about the impact of the hormone therapy on patients with PC quality life. In this way risks and benefits, ratio of a single therapy, have a greater significance. New biomarkers able to predict which patients may really benefit from a specific therapy without being exposed to an unnecessary toxicity, are required. For the future it should be possible to understand the genetic background of our patients with regard to some critical enzymes which could influence both response and resistance to drugs, before starting a specific therapy. This chance could make it really feasible to personalize the therapy in individual patients.
Aschelter et al. Genomic and epigenomic alterations in prostate cancer

Gross, M., Higano, C., Pantuck, A., Gregory, C. W., Johnson, R. T., Jr., Mohler, J. L., Fruchts, F. S., Wilson, E. M., et al. (2004). Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitive to low androgen. Cancer Res. 61, 2892–2898.

Fumoleau, P., et al. (2008). A phase I plus docetaxel in HER-2/neu-positive metastatic castration-resistant prostate cancer. Lancet Oncol. 9, 517–523.

Lee, L. C., Zhao, H., Nakajima, K., Oh, B. R., Ribereau Filho, L. A., and Carroll, P. (2001). Methylates of the E-cadherin gene promoter correlates with progression of prostate cancer. J. Natl. Cancer Inst. 93, 705–709.

Li, J., Gellen, J., Albert, J., and Krishnan, M. (1993). Acute effect of tetracene and adrenellar cortical blockade on protein synthesis and deloethioninase content of human prostate tissue. J. Endocrinol. Metab. 61, 129–133.

Locke, J. A., Gans, E. S., Lubik, A. A., Adamsen, H. H., Hindsy, S. C., Wood, C. A., et al. (2000). Androgen levels increase by intratumoral de novo steroidalogenesis during progression of castration-resistant prostate cancer. Cancer Res. 60, 6407–6415.

Lopergo, P. R., and Tindal, D. J. (2011). Androgen receptor signaling in prostate cancer development, and progression. J. Clin. Oncol. 29:10.

Mackintosh, A. C., Yin, B. C., Joseph, L. J., Al-Ahmadie, H. A., et al. (2009). Molecular biology underlying the clonogenicity of prostate cancer. Arch Pathol Lab Med. 135, 1035–1040.

Makridakis, N., Ross, R. K., Pico, M. C., Chang, J., Arancio, F., Zolotov, L., et al. (1997). A prevalent transgene substitution that modulates activity of prostate steroid 5α-reductase. Cancer Res. 57, 1020–1022.

Maniello, M., Minniti, M., Mariani, S., Sutherland, R., Nigam, R., Merity, L., et al. (2000). Androgen receptor mutations in prostate cancer. Cancer Res. 60, 944–949.

Mellinghoff, I. K., Vivanco, I., Koom, A., Tran, C., Wongpat, J., Sawyer, C. L., et al. (2004). HER2/neu dependence of androgen receptor function through effects on DNA binding and stability. Cancer Res. 64, 517–527.

Mildowski, M. J., Nunes, D. M., Kostokoplo, L., Vidalhavaous, S., Goldenh, S. J., and Ronder, N. H. (2004). Phase I trial of yttrium-90–labeled anti-prostate-specific- membrane-antigen monoclonal antibody 1991 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2312–2323.

Miyamoto, H., Yeh, S., Wilding, G., and Chang, C. (1995). Promotion of agent activity of antiangiogens by the androgen receptor coactivators, AIB1 and human prostate cancer DU145 cells. Proc. Natl. Acad. Sci. U.S.A. 92, 7379–7384.

Montgomery, K. B., Mostaghoul, E. A., Vossella, R., Hsu, D. L., Kallberg, T. F., Higano, C. S., et al. (2008). Maintenance of interstitial endogloin in metastatic prostate cancer: a mechanism of castration-resistant tumor growth. Cancer Res. 68, 6447–6450.

Nakamura, M., Bemett, C. J., Hicks, J. L., Epstein, J. I., Prits, E. A., Nelson, W. G., et al. (2003). Hypometa- bolism of the human glutathione S-transferase π gene (GSTP1). CPG island is present in a subset of prostatic tumors. J. Natl. Cancer Inst. 95, 1025–1025.

Palmquist, P., Xiong, B., and Rabbin, S. (2003). Methylation status of the apha promoter as a molecular marker regulating prostate cancer invasion and growth in vivo and in vitro. J. Urol. 170, 118–1188.

Palmberg, C., Kostov, P., Kakkaia, L., Temmola, T. L., Kalliomaki, O. P., and Vainkompsi, T. (2000). Androgen receptor gene amplification at partial prostate cancer. Cancer Res. 60, 944–949.

Parker, D., Ross, V., Stahouna, S., De Rosa, G., Chaff, P., Princosio, D., et al. (2006). The epigenetic marker of the luminal derived vascular endothelial growth factor (VEGF/VEGFR1) is associated with a favorable clinical outcome in prostate cancer. Eur. Urol. 49, 162–168.

Parker, R. H., Bitt, M., Blumberg, P., and Schullken, J. (1999). Molecular genetics and epidemiology of prostate cancer. J. Clin. Oncol. 17, 22–45.

Salhberg, M., Rechicki, C., Moram, R., Thalman, G., Padam, A., Roggen, E., et al. (2007). An open-label, noncomparative phase I trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with meniscal-refractory prostate cancer. Oncology 64, 150–154.

Schulman, S. S., Taplin, M. H., Jr., Utsop, E., et al. (2008). Antioxidant activity of SDM310 in castration-resistant prostate cancer.
prostate cancer: a phase 1–2 study. Lancer 273, 1457–1464.
Ignarotti, S., Montironi, R., Manola, J., Alliniari, A., Tam, C., Bulky, G., et al. (2005). 5α-neopla
expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 97, 1918–1925.
Small, E. J., and Scimemi, S. (1995). The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76, 1428–
1434.
Solli, D. B., and Roscn, N. (2007). Targeting HER2 in prostate cancer: where to next? J. Clin. Oncol. 25, 241–249.
Stevo, W. D. (2001). 5α-reductase activity in the prostate. Urology 58(Suppl), 17–24.
Suzuki, H., Freije, D., Nusskern, D. R., Okum, K., Caira, P., Ipadano, D., et al. (1998). Interferon he
heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204–209.
Suzuki, H., Ueda, T., Ichikawa, T., and Ita, H. (2003). Androgen receptor involvement in the progression of prostate cancer. Endocr. Relat. Cancer 10, 209–216.
Tagawa, S. T., Beltran, H., Va
labratory, 5, 1075–1085.
Tagawa, S. T., Milosevic, M. J., Morris, M., Valabrate, S., Goldsmith, S., Manoliu, D., et al. (2008). Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antgrp (PSMA) monoclonal anti
body 191I (77T4E-39I) in patients (pts) with metastatic castration-resistant prostate cancer (mCIPC). J. Clin. Oncol. 26(Suppl.), 284s.
Telfit, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spence, A. E., Ogera, G. K., et al. (1995). Muta
tion of the androgen receptor gene in metastatic, androgen-independent prostate cancer. N. Eng. J. Med. 332, 1395–1398.
Taylor, B. S., Shuster, N., Hroozynman, H., Gopalak, A., Xiao, J., Caven, B. S., et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22.
Teker, S., Lau, K. M., Long, J., Burnstein, K., and Hs, S. M. (2001). Expression of RFG/ELE I alpha/ARAN in normal and malign
ant prostatic epithelial cell cultures and lines: regulation by milataion and sex steroids. Mol. Carcinog. 30, 1–13.
Tino, M. A., Gregory, C. W., Ford, O. H. III, Allard, M. J., Margradan, S. J., and Meisler, J. L. (2005). Stenol
5α-reductase isoymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11, 4635–4671.
Tomlin, S. A., Rhod, D. B., Peraz, S., Dhanasukhan, S. M., Melra, R., Sun, K. W., et al. (2005). Reversal of TMRES2 and EMS transcrition factor genes in prostate cancer. Science 308, 644–648.
Trachtenberg, J. J., and Fong, A. P. (2004). Ketnonoar therapy for advanced prostate cancer. Lancer 2, 435–439.
van der Kast, T. H., Schalken, J., Ruizozav de Winter, J. A., van Vroonhoven, C. C., Malher, E., Boersma, W., et al. (1991). Androgen receptor in endocrine therapy resista

tant human prostate cancer. Int. J. Cancer 48, 189–195.
Wang, P., Zuo, Y. F., Feng, X. L., Su, H., and Huang, F. (2011). CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 58 independent studies. Prostate 71, 1107–1177.
Wen, Y., Hu, M. C., Makino, K., Spohn, R., Bartholomew, G., Yen, D. H., et al. (2000). HER-2/neu pre
motes androgen-independent survi
val and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60, 6481–6485.
Wright, J. L., Kwon, E. M., Lin, D. W., Kolb, S., Koopmeiners, J. S., Fong, Z., et al. (2010). CYP17 polymorphisms and prostate can
cer outcomes. Prostate 70, 1104–
1101.
Yamakawa, M., Hara, T., Hitaka, T., Kaki, T., Takanishi, T., Takahashi, J., et al. (2012). Oretanrol (Dak-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus mon
keys. J. Steroid Biochem. Mol. Biol. 129, 115–128.
Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. (1998). From HER2/Neu signal cascade to androgen receptor and its coactiva
tors: a novel pathway by induced of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 5430–5435.
Zhao, X. Y., Malloy, P. J., Krimm
man, A. V., Swaan, S., Navness, N. M., Poshi, D. M., et al. (2005). Glucocorticoids can promote andro
gen-independent growth of prostate cancer cells through a maintained androgen receptor. Nat. Med. 11, 705–708.
Ziaula, A., Bargur, A., Glode, L. M., Vanek-Garcia, M., Coughlin, F., Majorski, S., et al. (2004). The use of transretinylum in the treat
ment of hormone refractory prostate cancer: phase II trial. Prostate 60, 352–357.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any com
mercial or financial relationships that could be construed as a potential con
flict of interest.

Received: 18 April 2012; accepted: 10 October 2012; published online: 9 November 2012.
Citation: Aschelter AM, Giacinti S, Caporello P and Marchetti P (2012) Genomic and epigenomic alterations in prostate cancer. Front. Endocrinology, 3:128.

Copyright © 2012 Aschelter, Giacinti, Caporello and Marchetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, pro
vided the original authors and source are credited and subject to any copy
right notices concerning any third-party graphics.